Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Plus Therapeutics Inc
PSTV | US
6.60
USD-0.68
-9.34%
PSTV | US
Loading StockChartView...
About Plus Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
6.60
Open
7.28
High
7.28
Low
6.40
Plus Therapeutics Inc. a clinical-stage pharmaceutical company focuses on the development manufacture and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda a patented radiotherapy that targets central nervous system cancers including recurrent glioblastoma leptomeningeal metastases and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics Inc. and changed its name to Plus Therapeutics Inc. in July 2019. Plus Therapeutics Inc. was founded in 1996 and is headquartered in Austin Texas.
View LessPSTV | US
Risk
7670.9
Sharpe
0.25
Luna's Score
46/100
Recommendation
Hold
Luna says (PSTV | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
144.3%1 month
7670.9%3 months
4500.1%6 months
3221.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.76
Debt to equity
-0.45
Debt to assets
0.31
Ent. to EBITDA
-0.30
Ent. to rev.
18.19
PEG
-
Other Fundamentals
EBITDA
-13.47M
MarketCap
38.92M
MarketCap(USD)
38.92M
Div. yield
-
Op. margin
-289.05
Erngs. growth
-
Rev. growth
-31.00
Ret. on equity
-522.50
Short ratio
1.20
Short perc.
1.65
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.90
Range1M
7.76
Range3M
7.79
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.13
Price X volume
1.49M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.30 | 0.53 | Cheaper |
| Ent. to Revenue | 18.19 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.76 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 4,500.12 | 72.80 | Riskier |
| Debt to Equity | -0.45 | -1.23 | Expensive |
| Debt to Assets | 0.31 | 0.25 | Expensive |
| Market Cap | 38.92M | 3.66B | Emerging |
